Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

BUY
$20.37 - $32.9 $163,713 - $264,417
8,037 New
8,037 $237,000
Q3 2022

Nov 02, 2022

BUY
$17.49 - $28.44 $42,763 - $69,535
2,445 Added 7.32%
35,857 $834,000
Q2 2022

Aug 01, 2022

SELL
$12.95 - $46.99 $6.71 Million - $24.3 Million
-518,003 Reduced 93.94%
33,412 $561,000
Q1 2022

May 04, 2022

SELL
$40.12 - $59.5 $688,178 - $1.02 Million
-17,153 Reduced 3.02%
551,415 $23.5 Million
Q4 2021

Feb 07, 2022

BUY
$41.7 - $61.14 $17.3 Million - $25.4 Million
414,845 Added 269.87%
568,568 $34.6 Million
Q3 2021

Nov 02, 2021

SELL
$27.95 - $44.24 $465,423 - $736,684
-16,652 Reduced 9.77%
153,723 $6.39 Million
Q2 2021

Aug 03, 2021

SELL
$27.0 - $32.28 $259,659 - $310,436
-9,617 Reduced 5.34%
170,375 $5.17 Million
Q1 2021

May 04, 2021

BUY
$19.12 - $30.25 $205,387 - $324,945
10,742 Added 6.35%
179,992 $5.38 Million
Q4 2020

Feb 01, 2021

BUY
$17.95 - $21.36 $314,484 - $374,227
17,520 Added 11.55%
169,250 $3.04 Million
Q3 2020

Nov 09, 2020

SELL
$15.3 - $20.8 $854,550 - $1.16 Million
-55,853 Reduced 26.91%
151,730 $2.89 Million
Q2 2020

Aug 07, 2020

SELL
$12.63 - $18.21 $153,467 - $221,269
-12,151 Reduced 5.53%
207,583 $3.23 Million
Q1 2020

May 04, 2020

BUY
$9.82 - $18.0 $827,217 - $1.52 Million
84,238 Added 62.17%
219,734 $3.21 Million
Q4 2019

Feb 06, 2020

SELL
$7.68 - $11.08 $170,027 - $245,300
-22,139 Reduced 14.04%
135,496 $1.28 Million
Q4 2019

Feb 04, 2020

BUY
$7.68 - $11.08 $139,307 - $200,980
18,139 Added 13.0%
157,635 $1.72 Million
Q2 2019

Aug 15, 2019

BUY
$10.06 - $14.63 $1.4 Million - $2.04 Million
139,496 New
139,496 $1.4 Million

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $674M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.